Cargando…
Progress in treatment of small-cell lung cancer: role of CPT-11
Small-cell lung cancer (SCLC) accounts for approximately 15% of all cases of lung cancer and is a particularly aggressive form of lung cancer characterised by a poor prognosis, rapid tumour growth, and early metastasis. Roughly, two-thirds of patients with SCLC present with extensive disease (ED) an...
Autor principal: | Saijo, N |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395289/ https://www.ncbi.nlm.nih.gov/pubmed/14676791 http://dx.doi.org/10.1038/sj.bjc.6601456 |
Ejemplares similares
-
Progress in immunotherapy for small cell lung cancer
por: Zhao, Dong, et al.
Publicado: (2020) -
Progress in image-guided radiotherapy for the treatment of non-small cell lung cancer
por: Ren, Xiao-Cang, et al.
Publicado: (2019) -
Emerging ethnic differences in lung cancer therapy
por: Sekine, I, et al.
Publicado: (2008) -
A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group.
por: Masuda, N., et al.
Publicado: (1998) -
Current treatment landscape for oligometastatic non-small cell lung cancer
por: Garde-Noguera, Javier, et al.
Publicado: (2022)